ACT Accelerator

ACT Accelerator
Alexey Solodovnikov (Idea, Producer, CG, Editor), Valeria Arkhipova (Scientific · CC BY-SA 4.0 · source
Name	ACT Accelerator
Founded	2020
Founders	World Health Organization, Gavi, the Vaccine Alliance, Coalition for Epidemic Preparedness Innovations, The Global Fund, Wellcome Trust
Type	Public–private partnership
Region	Global

ACT Accelerator

The ACT Accelerator was launched in 2020 as a multilateral public–private initiative to accelerate development, production, and equitable access to diagnostics, therapeutics, and vaccines during the COVID-19 pandemic, coordinating responses among major global health actors. It brought together agencies such as the World Health Organization, Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations, and The Global Fund alongside philanthropic funders like the Wellcome Trust and national actors including the United States Department of Health and Human Services, European Commission, and governments of United Kingdom, Germany, and Japan to address gaps in research, procurement, and delivery. The initiative sought to bridge pharmaceutical capacity in regions such as Sub-Saharan Africa, South Asia, and Latin America while engaging multilateral institutions like the International Monetary Fund and the World Bank.

Background and Purpose

The initiative emerged amid global alarm following the declaration of the COVID-19 pandemic and high-profile outbreaks that involved institutions such as Centers for Disease Control and Prevention and National Institutes of Health. It aimed to coordinate biomedical innovation pathways among stakeholders including Pfizer, Moderna, AstraZeneca, Johnson & Johnson, and research consortia tied to universities like University of Oxford, Harvard University, and University of Cambridge. The purpose addressed challenges observed during prior outbreaks involving Ebola virus epidemic in West Africa and the H1N1 flu pandemic, leveraging mechanisms developed by entities such as the Access to Medicine Foundation and financial models used by Gavi, the Vaccine Alliance and The Global Fund to promote equitable distribution to low- and middle-income countries represented within forums like the African Union and the Pan American Health Organization.

Governance and Structure

Governance combined leadership from World Health Organization and technical partners including Gavi, the Vaccine Alliance and Coalition for Epidemic Preparedness Innovations, with oversight input from ministries such as Ministry of Health (United Kingdom), Ministry of Health (Brazil), and Ministry of Health, Labour and Welfare (Japan). A steering group featured representatives from Bill & Melinda Gates Foundation, Wellcome Trust, and delegations from European Commission and the United States. Operational arms paralleled established structures at Gavi and The Global Fund for procurement and deployment, while advisory bodies included experts associated with Johns Hopkins Bloomberg School of Public Health, London School of Hygiene & Tropical Medicine, and Imperial College London.

Funding and Financial Mechanisms

Financing drew on contributions from sovereign donors such as United States, United Kingdom, Germany, France, Japan, and pooled philanthropic support from Bill & Melinda Gates Foundation and Wellcome Trust. Mechanisms included advance purchase agreements used previously by Gavi, the Vaccine Alliance and market-shaping tools similar to those employed by Pooled Procurement Mechanism and Advance Market Commitment programs. Financial coordination engaged multilateral lenders like the World Bank and grant-management entities such as UNICEF and UNDP, while private sector investment came from pharmaceutical firms including Pfizer and Moderna and diagnostics companies like Roche and Abbott Laboratories.

Core Pillars and Initiatives

The initiative organized workstreams modeled on biomedical divisions including vaccine acceleration, therapeutics, diagnostics, and health systems delivery. Vaccine workstreams coordinated clinical trials run by consortia linked to University of Oxford and manufacturers such as AstraZeneca and Moderna, while therapeutics tracks prioritized repurposed drugs evaluated in platform trials like RECOVERY trial and regulatory pathways involving European Medicines Agency and U.S. Food and Drug Administration. Diagnostics efforts partnered with companies like Roche and research groups at Imperial College London to expand PCR and antigen testing capacity. Delivery and health systems components collaborated with UNICEF, World Food Programme, and country immunization programs coordinated by Ministries of Health and regional offices of the World Health Organization.

Partnerships and Stakeholders

Key stakeholders comprised public health agencies, bilateral donors, philanthropic foundations, research institutions, and private industry. Partner organizations included World Health Organization, Gavi, the Vaccine Alliance, Coalition for Epidemic Preparedness Innovations, The Global Fund, UNICEF, World Bank, Wellcome Trust, and pharmaceutical companies such as Pfizer, Moderna, AstraZeneca, and Johnson & Johnson. Academic participants included Harvard University, Imperial College London, University of Oxford, and Johns Hopkins University. Regional partners involved African Union, PAHO, and national health systems across India, Brazil, South Africa, and Indonesia.

Impact, Outcomes, and Criticism

Outcomes cited include accelerated development and distribution of vaccines and diagnostics, expanded manufacturing agreements in regions like South Africa and India, and procurement volumes managed through partnerships with UNICEF and Gavi, affecting national rollout plans in countries such as Kenya and Bangladesh. Critics highlighted concerns about unequal access reminiscent of debates during the H1N1 flu pandemic and structural power imbalances between high-income donors and low-income recipients, invoking commentary from organizations like the Access to Medicine Foundation and civil society groups including Médecins Sans Frontières. Policy analysts at institutions such as Chatham House and Center for Global Development assessed transparency, governance, and the sufficiency of funding versus needs identified by the World Health Organization and UN bodies. Proponents pointed to partnerships with manufacturing initiatives in South Africa and technology transfer discussions involving entities like Biovac and Serum Institute of India as evidence of progress toward more resilient global health supply chains.

Category:Public–private partnerships